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Abstract
Background: Dental pulp represents an easily accessible autologous source of adult stem cells. A subset of these
cells, named dental pulp pluripotent-like stem cells (DPPSC), shows high plasticity and can undergo multiple population
doublings, making DPPSC an appealing tool for tissue repair or maintenance.
Methods: DPPSC were harvested from the dental pulp of third molars extracted from young patients. Growth factors
released by DPPSC were analysed using antibody arrays. Cells were cultured in specific differentiation media and their
endothelial, smooth and skeletal muscle differentiation potential was evaluated. The therapeutic potential of DPPSC
was tested in a wound healing mouse model and in two genetic mouse models of muscular dystrophy (Scid/mdx and
Sgcb-null Rag2-null γc-null).
Results: DPPSC secreted several growth factors involved in angiogenesis and extracellular matrix deposition and
improved vascularisation in all three murine models. Moreover, DPPSC stimulated re-epithelialisation and ameliorated
collagen deposition and organisation in healing wounds. In dystrophic mice, DPPSC engrafted in the skeletal muscle of
both dystrophic murine models and showed integration in muscular fibres and vessels. In addition, DPPSC treatment
resulted in reduced fibrosis and collagen content, larger cross-sectional area of type II fast-glycolytic fibres and infiltration
of higher numbers of proangiogenic CD206+ macrophages.
Conclusions: Overall, DPPSC represent a potential source of stem cells to enhance the wound healing process and
slow down dystrophic muscle degeneration.
Keywords: Dental pulp, Stem cells, Revascularisation, Angiogenesis, Wound healing, Muscular dystrophy, Growth factors,
Cytokines
Background
Dental pulp pluripotent-like stem cells (DPPSC) [1] have
been recently isolated from the dental pulp of human
third molars and express pluripotency markers such as
OCT3/4, SOX2 and NANOG. DPPSC show pluripotent-
like behaviour, as they can differentiate in vitro into tis-
sues of the three embryonic germ layers and are able to
form embryoid body-like and teratoma-like structures
[2]. This population represents an easily accessible au-
tologous source of adult stem cells and is not touched
by the ethical controversy that is associated with the use
of embryonic stem cells.
The restoration of organ function requires effective
revascularisation, the generation of new blood vessels
formed mainly by endothelial cells (ECs) and smooth
muscle cells (SMCs). Currently, there is a growing list of
highly prevalent diseases with a blood vessel-related
aetiology [3]. Indeed, more than 500 million people
worldwide would benefit from pro- or anti-angiogenic
treatments [4]. Moreover, blood vessels represent an es-
sential component of tissue engineering. If blood supply
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cannot be rapidly established in an implanted tissue, ne-
crosis will occur due to insufficient oxygen and nutrient
transport [5]. So far, available vascular grafts cannot re-
produce the complex functions of native vessels [6], and
in this regard it has been proven that the presence of
functional ECs in the grafts can improve these functions
[7]. Since autologous sources of ECs are insufficient or
very difficult to obtain [8], stem cell differentiation has
been explored in order to increase their number [9–12].
Tissue regeneration and stimulation of blood vessel
growth are critical factors for the successful treatment of
wounds [13] and skeletal muscle degeneration [14].
Wound healing is a complex and organised process that
restores integrity and function of the damaged tissue
[15]. It restores the barrier function of the skin by re-
epithelialisation, revascularisation, matrix deposition/re-
modelling and contraction. These processes involve the
interaction of different cell types including ECs, SMCs,
platelets, inflammatory cells, (myo)fibroblasts and kerati-
nocytes. These cells secrete vascular endothelial growth
factor (VEGF), basic fibroblast growth factor (bFGF),
platelet-derived growth factor (PDGF), placental growth
factor (PlGF), transforming growth factor beta (TGF-β)
and tissue inhibitor of metalloproteinases 2 (TIMP-2)
among other factors to regulate the healing process and
modulate the extracellular matrix components [16–18].
For healing of large wound defects, autologous tissue-
engineered skin grafts are needed. After grafting, quick
and functional vascularisation needs to be achieved to
help tissue-engineered skin to survive [19]. The use of
mesenchymal stromal cells (MSCs) has been shown to
promote wound healing through different processes, in-
cluding angiogenesis [20]. Muscular dystrophies (MDs)
are genetic diseases that cause progressive weakness and
degeneration of skeletal muscles. Mutations in the dys-
trophin gene underlie Duchenne muscular dystrophy
(DMD), the most common and severe form of muscular
dystrophies. Other dystrophies feature mutations in
genes encoding sarcoglycans [21] and are included in
the group of limb-girdle muscular dystrophies (LGMDs).
LGMD type 2E (LGMD2E), with a mutation in the beta-
sarcoglycan (SGCB) gene, represents a severe form of
LGMD [22, 23], often associated with cardiomyopathy
and abnormalities in the vasculature [23–25]. Currently,
there is no cure for DMD or LGMD2E [26, 27] and effect-
ive therapeutic approaches capable of counteracting
muscle and vessel degeneration are needed. In this regard,
stem cell therapy can be used to restore dystrophin or
beta-sarcoglycan in dystrophic muscles, thereby repairing
the damaged fibres and preventing future muscle
degeneration.
In this study, we investigated the therapeutic potential
of DPPSC in a model of wound healing in nude mice,
and in immunodeficient mice resembling DMD and
LGMD2E disorders, Scid/mdx [28] and Sgcb-null Rag2-
null γc-null [29], respectively.
Methods
Patient selection
DPPSC were isolated from healthy human third molars
extracted for orthodontic and prophylactic reasons from
15 patients with ages between 14 and 21 years old. All
patients (or their legal guardians) provided informed
consent before obtaining the samples. This study was
approved by the Committee on Ethics in Research (CER)
of the Universitat Internacional de Catalunya (Spain)
under the protocol code BIO-ELB-2013-04.
Isolation and culture of DPPSC
DPPSC were extracted and isolated as previously de-
scribed [2]. Briefly, teeth were washed after extraction
using gauze soaked in 70% ethanol and dental pulp was
extracted from the teeth using a sterile nerve-puller file
15 and forceps (if the apexes were still open) or fractur-
ing the teeth and taking the dental pulp using forceps.
The dental pulp was placed in sterile 1X phosphate-
buffered saline (PBS; Life Technologies, Carlsbad, CA,
USA) with 5% of 0.25% trypsin-EDTA (Life Technolo-
gies) and 1% penicillin-streptomycin (Life Technologies)
and transferred to the laboratory. The tissues were dis-
aggregated by digestion with collagenase type I (3 mg/
mL; Sigma-Aldrich, St. Louis, MO, USA) for 60 minutes
at 37 °C. Obtained cells were cultivated in DPPSC
medium, which consisted of 60% Dulbecco’s modified
Eagle’s medium (DMEM)-low glucose (Life Technolo-
gies) and 40% MCDB-201 (Sigma-Aldrich) supple-
mented with 1 × insulin-transferrin-selenium (ITS;
Sigma-Aldrich), 1 × linoleic acid-bovine serum albumin
(LA-BSA; Sigma-Aldrich), 10-9 M dexamethasone
(Sigma-Aldrich), 10-4 M ascorbic acid 2-phosphate
(Sigma-Aldrich), 100 units of penicillin/1000 units of
streptomycin (Life Technologies), 2% foetal bovine
serum (FBS; Sigma-Aldrich), 10 ng/mL human PDGF-
BB (Abcam, Cambridge, UK), 10 ng/mL epidermal
growth factor (EGF; R&D Systems, Minneapolis, MN,
USA), 1000 units/mL human leukemia inhibitory factor
(LIF; EMD Millipore, Billerica, MA, USA), Chemically
Defined Lipid Concentrate (Life Technologies), 0.8 mg/
mL BSA (Sigma-Aldrich) and 55 mM β-
mercaptoethanol (Sigma-Aldrich) in 650 mL flasks pre-
coated overnight with 100 ng/mL fibronectin at 37 °C in
a 5% CO2 incubator. During the 2 weeks of primary cul-
ture, the medium was changed every 4 days. To propa-
gate DPPSC, the cells were detached at 30% confluence
by adding PBS containing 0.25% trypsin-EDTA (Life
Technologies) and replated at a density of 100–150
cells/cm2. Cell populations from different donors at pas-
sage 5 and passage 10 were negative for mycoplasma
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contamination (MycoAlert™ Mycoplasma Detection Kit,
Lonza, Basel, Switzerland).
Culture of HUVECs
Human umbilical vein endothelial cells (HUVECs; Lonza;
tested for mycoplasma, bacteria, yeast, fungi, HIV-1,
hepatitis B and hepatitis C) were maintained in Endothe-
lial Growth Medium 2 (EGM-2; Lonza). The medium
was changed every 2 days and the cells were passaged
when they reached 70–85% confluence using PBS con-
taining 0.25% trypsin-EDTA (Life Technologies) and
replated at a density of 2.5 × 103 cells/cm2.
Culture of C2C12 cells
The mouse immortalised myoblast cell line C2C12 was
maintained using DMEM 4.5 g/L glucose supplemented
with 10% FBS (Hyclone, South Logan, UT, USA), 1%
glutamine (Sigma-Aldrich), 1% sodium pyruvate (Life
Technologies) and 1% penicillin/streptomycin (Life
Technologies). Cells were negative for mycoplasma
contamination (MycoAlert™ Mycoplasma Detection Kit,
Lonza).
Lentiviral transduction
DPPSC were seeded at a density of 500 cells/cm2 and
transduced at 60% confluence with lentiviruses encod-
ing for turbo green fluorescent protein (tGFP) from
Pontellina Plumata for 24 hours. Briefly, incompetent
viral particles were produced in packaging cells (HEK293T)
by co-transfecting the tGFP lentiviral vector plasmid
(Sigma-Aldrich shc003) with compatible Lentiviral
Packaging Mix (Sigma-Aldrich). This method allowed
generation of 100% GFP+ DPPSC that were used for the
wound healing assay.
In vitro EC differentiation
DPPSC were seeded in 24-well plates at 2 × 104 cells/cm2
and differentiated using EGM-2 (Lonza) conditioned
for 24 h with HUVECs (and then filtrated with 0.22-μm
diameter pores to eliminate any HUVECs). The
medium was changed every 2–3 days for 28 days. RNA
extraction and Matrigel™ assay were performed at day
7, 14, 21 and 28 of differentiation. Immunofluorescence
analysis was performed at day 28. For the Matrigel™
assay, DPPSC were detached using PBS containing
0.25% trypsin-EDTA (Life Technologies) and 50,000
cells were replated in EGM-2 medium in a 24-well
coated with Matrigel™ (Basement Membrane Matrix
Growth Factor Reduced; BD Biosciences, San Jose, CA,
USA). Matrigel™ coating was performed following man-
ufacturer’s instructions for the Thin Gel Method assay,
adding 250 μl of Matrigel™ in a 24-well and keeping it
30 minutes at 37 °C. After 24 hours, tube-like struc-
tures were analysed and pictures were taken with an
OX.3040 Euromex binocular microscope for phase con-
trast using the camera DC.10000c CMEX-10 digital 10
Mpix USB-2 CMOS (Euromex, Arnhem, The
Netherlands).
In vitro SMC differentiation
DPPSC from two different donors and two passages
(passage 5 and passage 10) were differentiated to SMCs
using differentiation media consisting of High-Glucose
DMEM (Life Technologies) supplemented with 2% horse
serum (Life Technologies), 1% sodium pyruvate (Life
Technologies), 1% glutamine (Life Technologies), 1%
penicillin-streptomycin (Life Technologies) and 50 ng/
mL TGF-β1 (Peprotech, Rocky Hill, NJ, USA). Cells were
plated in 24-well plates at 500 cells/cm2 and differenti-
ation was started when they reached 60% confluence.
Medium was changed every 2–3 days for 10 days. tGFP+
DPPSC from one of the donors were also differentiated
using the same conditions.
In vitro skeletal muscle differentiation
DPPSC from three different donors and two passages
(passage 5 and passage 10) were differentiated to skeletal
muscle using differentiation media consisting of High-
Glucose DMEM (Life Technologies) supplemented with
2% horse serum (Life Technologies), 1% sodium pyruvate
(Life Technologies), 1% glutamine (Life Technologies) and
1% penicillin-streptomycin (Life Technologies). Cells were
differentiated alone or in direct co-culture with C2C12
cells at 1:1 ratio. The cells were plated in 24-well plates at
a density of 1 × 104 cells/cm2 and induction was started
when cells reached 70% confluence. Medium was changed
every 2–3 days for 5–7 days. tGFP+ DPPSC from one of
the donors were also differentiated in the same conditions.
Fusion index was calculated as the ratio of the number of
nuclei inside the MyHC+ myotubes to the number of total
nuclei (percentage).
Wound healing assay
Eight-week-old male athymic nude mice (Foxn1, Charles
River Laboratories, Wilmington, MA, USA) were treated
with DPPSC (P10) or PBS (n = 5 for each condition).
The mice were injected with anti-NK to eliminate nat-
ural killer cell activity 24 hours before starting the sur-
gery. Full-thickness wounds (0.5-cm diameter) were
made on the back of the mice, splinted with silicone
rings and treated with tGFP+ DPPSC (1 × 106 cells per
mouse) or PBS. A Tegaderm™ dressing (3M, Maple-
wood, MN, USA) was applied to prevent the wound area
from drying out. All wounded mice were housed indi-
vidually to avoid fighting and to prevent removal of the
occlusive wound dressing. Every other day, digital pic-
tures of the wounds were taken (using a NikonD1 cam-
era and Camera-Control-Pro software; Nikon, Tokyo,
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Japan) under isoflurane anaesthesia and the dressings
were renewed. Presence of DPPSC was monitored at day
5 and 10 using a Zeiss SteREO Discovery.V12 micro-
scope and Axio Imaging software (Carl Zeiss, Ober-
kocken, Germany). Wound contraction was evaluated by
comparing relative wound area (RWA) over time. RWA
was calculated using ImageJ software (NIH, Baltimore,
MD, USA) by dividing the healing wound area by the
fixed reference area inside the silicone ring and express-
ing it as a percentage. To account for small inter-animal
variations, for each time point, relative wound area of
each individual animal was expressed as percentage
compared to the relative wound area at day 0. Wound
contraction (%) was calculated as the complement of
relative wound area (100-RWA). At day 11 after wound-
ing, mice were sacrificed and skin fragments including
the wound area and a rim of normal skin were dissected
out, fixed, separated in two pieces at the midline and
processed for paraffin embedding. For all stainings and
analyses, 7 μm microtome sections were used. Mouse
procedures were approved by the ethics committee for
use of animals in research from KU Leuven (Belgium)
under the protocol code ECD N°P018/2015.
DPPSC injection in dystrophic mice
Ten 3-month-old Scid/mdx mice, five males and five fe-
males, and four 3-month-old Sgcb-null Rag2-null γc-null
mice, three males and one female, were injected in the
left tibialis anterior with 2.5 × 105 cells per mouse.
DPPSC from P10 were used. Untreated right limbs were
used as controls. After 20 days, mice were sacrificed and
muscles were frozen and kept at -80 °C. The samples
were then cut in 7 μm sections using a cryostat (Leica,
Wetzlar, Germany). Mouse procedures were approved
by the ethics committee for use of animals in research
from KU Leuven (Belgium) under the protocol code
ECD N°P095/2012.
Short-comparative genomic hybridisation
The short-comparative genomic hybridisation (sCGH)
technique was performed as described in Rius et al. [30]
catching single cells from a homogeneous DPPSC cul-
ture. All samples were analysed in triplicate. The DNA
control used for the hybridisation was XXY.
Quantitative reverse transcription (qRT)-PCR analysis
Samples of total RNA were extracted using Trizol
(Life Technologies) and isolated following manufac-
turer’s instructions. Two μg of total RNA with a ratio
260/280 between 1.8 and 2 were treated with DNase
I (Life Technologies) and reverse-transcribed using
Transcriptor First Strand cDNA Synthesis Kit (Roche,
Basel, Switzerland). Polymerase chain reaction (PCR)
was performed using the primers in Additional file 1:
Table S1 for the amplification of the desired cDNA
using FastStart Universal SYBR Green Master (Roche)
for Real-Time PCR using a CFX96 Real-Time PCR
Detection System (Bio-Rad, Hercules, CA, USA). The
expression levels of the genes of interest were nor-
malised against the housekeeping gene GAPDH and
the relative expression levels were then normalised to
undifferentiated DPPSC at P5 or at day 0 of differen-
tiation, which were assigned as 1. All analyses were
performed using the 2(-ΔΔCT) method and three tech-
nical replicates.
Cytokine antibody arrays
Undifferentiated DPPSC (1.5 × 106 cells) from three
different donors were cultured for 48 hours in DPPSC
medium without FBS, LIF or BSA. tGFP+ DPPSC
were also used. The presence of several growth fac-
tors and cytokines secreted in the medium was ana-
lysed using human cytokine antibody arrays
containing 80 target proteins (Abcam ab133998).
Briefly, the supplied membranes (spotted with 80 dif-
ferent antibodies) were blocked with the provided
buffer and subsequently incubated at 4 °C overnight
with 1 ml of the DPPSC medium in contact with
DPPSC for 48 hours. One of the membranes was in-
cubated with an uncultured medium and used as a
control. Membranes were washed with the provided
buffers and incubated again at 4 °C overnight with
the supplied biotin-conjugated anti-cytokines. The ar-
rays were then washed, incubated with horseradish-
peroxidase-conjugated streptavidin for 2 hours at
room temperature and washed. Chemiluminescence
reaction was detected using the supplied detection
buffers. Semi-quantification by relative densitometry
was obtained using Quantity One software (Bio-Rad)
and normalised to the positive control signals in each
membrane for comparison of multiple arrays and to
EGF.
The presence of cytokines in lysates from DPPSC-
injected and control muscles of dystrophic mice (three
Sgcb-null Rag2-null γc-null mice and one Scid/mdx
mouse) was also analysed using mouse cytokine antibody
arrays containing 22 target proteins (Abcam ab133993).
Briefly, muscle lysates were obtained by mechanical
homogenisation in RIPA buffer (Sigma-Aldrich) supple-
mented with and 1 mM phenylmethanesulfonyl fluoride,
0.5 mM sodium orthovanadate, 1:100 protease inhibitor
cocktail and 10 mM sodium fluoride (Sigma-Aldrich)
using a T10 basic Ultra-Turrax homogeniser (IKA, Stau-
fen, Germany). Subsequently, samples were sonicated
(Branson digital sonifier 250; Branson Ultrasonics, Dan-
bury, CT, USA) two times for 10 seconds each, kept on
ice for 30 minutes, centrifuged at 13000 × g for 10 mi-
nutes at 4 °C and supernatants were collected. Protein
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concentrations were determined using the Bradford
assay (Bio-Rad) and equal amounts of protein (300 μg)
were incubated at 4 °C overnight with the supplied mem-
branes (previously blocked). Subsequent steps were per-
formed following the same protocol used with the human
cytokine arrays.
Immunofluorescence analyses
Cryosections and cells were fixed with 4% paraformalde-
hyde for 15 minutes or ethanol-acetone 1:1 for 4 minutes
at room temperature and then, after three PBS washes,
incubated with 1% BSA + 0.2% or 0.5% triton for 30–45
minutes at room temperature to increase permeability.
Cells were then incubated for 30–60 minutes with don-
key serum at room temperature and, after that, 2 hours
at room temperature or 4 °C overnight with the primary
antibody (Additional file 2: Table S2). The following day,
after three PBS washes, they were incubated for 1–2
hours at room temperature with the secondary antibody
and washed again three times. DAPI (1:3000) was used
for nuclear counterstaining, washed three times and
wells containing cells or slides were mounted using
FluorSave™ mounting medium (EMD Millipore). Paraffin-
embedded sections were deparaffinised and rehydrated,
followed by an antigen recovery step (putting the slides in
citrate buffer pH = 6 for 20 minutes in the microwave, in
trypsin 1:80 in 0.01% CaCl2 at 37 °C for 7 minutes or in
target retrieval solution (Dako, Glostrup, Denmark) for
20 minutes at 95 °C). Samples were washed with Tris-
buffered saline (TBS), incubated for 20 minutes with
MeOH-H2O2 and washed again. They were then per-
meabilised using 0.5% triton, washed with TBS, blocked in
20% donkey serum or Tris-NaCl blocking buffer and
incubated with the primary antibody (Additional file 2:
Table S2) 2 hours or overnight at room temperature. Sam-
ples were washed with Tris-NaCl-Tween buffer, incubated
with the secondary antibody and washed again. CD31,
laminin and collagen type I and III signals were amplified
using TSA Fluorescein System (Perkin Elmer, Waltham,
MA, USA). Samples were mounted using Prolong Gold
with DAPI (Life Technologies). Pictures were taken with
an Eclipse Ti Microscope (Nikon) and NIS-Elements AR
4.11 software. Images were merged and/or quantified
using ImageJ software (NIH).
Alkaline phosphatase staining
SIGMAFAST™ BCIP®/NBT (Sigma-Aldrich) was used
following manufacturer’s instructions. Briefly, one tablet
was dissolved in 10 mL of water, and 1 mL was added in
one 24-well plate containing undifferentiated DPPSC.
The solution was kept for 2 hours at 37 °C and the wells
were washed afterwards with PBS. Fibroblasts were used
as a negative control.
Haematoxylin and eosin staining
Paraffin sections were heated at 57 °C for 60 minutes,
deparaffinised and rehydrated. Cryosections were fixed
with 4% paraformaldehyde for 15 minutes. The samples
were then soaked in distilled water for 5 minutes, Harris
haematoxylin for 4 minutes and washed afterwards in
running tap water for 2 minutes. The sections were
subsequently soaked for 1 minute each in acid alcohol,
running water, bluing reagent, running water, eosin, 95%
ethanol, 100% ethanol and histoclear. The slides were
then mounted with DPX and left on a slide heater
overnight. Pictures from paraffin sections were taken
with a Leica DMRBE microscope connected with an
AxioCam MRc5 camera (Zeiss). Pictures from cryosec-
tions were taken with a Nikon Eclipse Ti micro-
scope (Nikon). Epithelial coverage and thickness and
cross-sectional area were determined using ImageJ soft-
ware (NIH).
Sirius red staining
Sirius Red solution was prepared by mixing 0.2 g of
Direct Red 80 (Sigma-Aldrich) with saturated aqueous
solution of picric acid (prepared mixing 8 g of picric acid
in 200 mL of distilled water). Paraffin sections were
deparaffinised and rehydrated and crysections were fixed
with 4% paraformaldehyde for 15 minutes. Sections were
put in tap water for 10 minutes, distilled water for 5 mi-
nutes and Sirius Red solution for 90 minutes. After that,
the slides were washed with HCL 0.01 N for 2 minutes
and dehydrated with ethanol 70% for 45 seconds and
ethanol 100% for 5 minutes (twice). Lastly, samples were
cleared in xylol for 5 minutes (twice), mounted with
DPX and left on a slide heater overnight. Pictures were
taken with a Leica DMRBE microscope connected with
an AxioCam MRc5 camera (Zeiss). Collagen quantifica-
tion was determined using ImageJ software (NIH).
Masson’s trichrome staining
Cryosections were fixed with 4% paraformaldehyde for
15 minutes and subsequently incubated for 15 min at 57
°C in Bouin solution. Afterwards, cryosections were
stained in Working Weigert's Iron Hematoxylin Solution
for 5 minutes, washed in running tap water for 5 minutes
and stained in Biebrich Scarlet-Acid Fucsin for 5 mi-
nutes. Slides were subsequently soaked in de-ionised
water and in Working Phosphotungstic\Phosphomolyb-
dic acid solution for 5 minutes and stained in Aniline
Blue solution for 5 minutes and acid acetic 1% for 2 mi-
nutes. Slides were mounted and left in a slide heater
overnight. Pictures were taken on a Nikon Eclipse Ti
microscope (Nikon). Fibrotic area was quantified using
ImageJ software (NIH).
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Esterase staining
Cryosections were rehydrated and left in PBS for 5 mi-
nutes. A staining solution of 5 mL containing 2 mg
NADH (Sigma-Aldrich) with 4 mg NBT (Roche) in
4.5 mL H2O and 0.5 mL 1 M Tris-HCl pH = 7.5 was pre-
pared. Drops of prepared solution were added to the sec-
tions, which were then incubated for 30–60 minutes at
37 °C incubator. Samples were washed with H2O twice,
dehydrated in ascending scale of alcohol (50%, 80%, 90%
and 100%) for 1 minute each and then alcohol was re-
moved with histoclear. Slides were mounted with DPX
and left to dry in a heater. Pictures were taken on a Nikon
Eclipse Ti microscope (Nikon). Cross-sectional area was
calculated using ImageJ software (NIH).
Statistical analyses
Data from the different experiments were analysed using
the statistical program Statgraphics Centurion XVI
(Statgraphics, Warrenton, VA, USA). Two-tailed t test or
one-way ANOVA were used to compare interrelated sam-
ples, while two-way ANOVA was used to analyse multiple
factors. Confidence intervals were fixed at 95% (p < 0.05),
99% (p < 0.01) and 99.9% (p < 0.001). GraphPad Prism
(GraphPad Software, San Diego, CA, USA) was used to
graph the results as the mean ± standard error of the
mean (s.e.m.). Refer to figure legends for specific informa-
tion regarding the statistical test used and the number of
independent experiments or biological replicates.
Results
Characterisation of DPPSC and their in vitro
differentiation potential
As described before, DPPSC had a small size with large
nuclei and low cytoplasm content and this morphology
was maintained for more than 15 passages (Additional
file 3: Figure S1a-d). The growth rate of DPPSC
populations from 13 different donors until passage 15
was analysed (Additional file 3: Figure S1e, f ). Ten
DPPSC populations were analysed by short-comparative
genomic hybridisation (sCGH) and none of them
showed chromosomal abnormalities (a representative ex-
ample is shown in Additional file 3: Figure S1g). DPPSC
expressed pluripotency markers OCT4A and NANOG in
all passages analysed, although their expression was
found to be significantly higher at passage 10 compared
to other passages (Additional file 3: Figure S1h). Im-
munofluorescence analyses confirmed the presence of
NANOG and SOX2 proteins in DPPSC (Additional
file 3: Figure S1i, j). DPPSC were also positive for al-
kaline phosphatase (ALP) enzymatic staining (Additional
file 3: Figure S1k). To get insights into DPPSC secretion
we analysed which molecules can be produced by these
cells. Analysis with human cytokine antibody arrays
showed angiogenin (ANG), VEGF, PDGF-BB, hepatocyte
growth factor (HGF), monocyte chemoattractant protein
1 (MCP-1), osteoprotegerin, tissue inhibitor of metallo-
proteinases 1 (TIMP-1) and TIMP-2 as main molecules
secreted by DPPSC (Fig. 1a, b). The quantification of these
molecules revealed that DPPSC released in the medium
more than 4 μg/ml of ANG, PDGF-BB, HGF, MCP-1,
TIMP-1 and TIMP-2 (Fig. 1c).
DPPSC subjected to culture conditions favouring
endothelial differentiation showed a significant up-
regulation of the endothelial markers von Willebrand
factor (vWF) starting at day 14 and CD31 at day 21
(Additional file 4: Figure S2a). A significant up-
regulation of vascular endothelial growth factor receptor
2 (VEGFR2) was also observed at day 28 of the differen-
tiation (Additional file 4: Figure S2a). Unlike in undiffer-
entiated DPPSC, at day 28, we were able to detect
endothelial markers CD31, vWF and vascular endothelial
cadherin (VE-cadherin) by immunofluorescence analyses
in a subset of cells (Fig. 2a-c, j). The percentage of vWF+
VE-cadherin+ cells and CD31+ VE-cadherin+ was 13.7%
± 4.6% and 12.2% ± 3.3%, respectively (Fig. 2j). Finally, as
endothelial differentiation progressed, cells had a ten-
dency to form more tubular-like structures on Matrigel™
(Additional file 4: Figure S2b-d), and after 4 weeks the
extent of tube formation was comparable to that of
human umbilical vein endothelial cells (HUVECs;
Additional file 4: Figure S2d-f ).
DPPSC subjected to SMC differentiation conditions be-
came bigger and flatter at day 4. At day 10 of differenti-
ation, immunofluorescence analyses for α-smooth muscle
actin (αSMA) and calponin revealed that differentiated
DPPSC populations contained a high number of SMCs, in
contrast to undifferentiated cells (Fig. 2d-f, k and Add-
itional file 5: Figure S3a-d). We also observed that passa-
ging or transduction with a tGFP-encoding reporter virus
did not significantly affect the SMC differentiation poten-
tial of DPPSC (Fig. 2 k and Additional file 5: Figure S3d).
DPPSC cultured alone for 7 days in myogenic differ-
entiation medium showed rare multinucleated cells
positive for myosin heavy chain (MyHC; Additional
file 5: Figure S3e, f ). DPPSC co-cultured with C2C12
cells (a mouse myoblast cell line) revealed better qual-
ity of myotubes compared to control C2C12 cells at
day 3 and 4 of myogenic induction (Additional file 5:
Figure S3g-j). At day 5 of differentiation, immuno-
fluorescence analyses showed MyHC+ multinucleated
myotubes containing human nuclei, unlike in undif-
ferentiated DPPSC (Fig. 2g, i and Additional file 5:
Figure S3k-m). tGFP+ myotubes were also observed in
co-cultures using tGFP+ DPPSC (Fig. 2h), confirming
that DPPSC can fuse into myotubes. DPPSC from dif-
ferent donors and passages showed comparable results
(Fig. 2g and Additional file 5: Figure S3k-m). Fusion
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index (Fig. 2l) and the number of MyHC+ myotubes
(Fig. 2m) of the co-cultures were significantly higher
compared to control C2C12 cells.
The healing potential of DPPSC in skin wounds
Full-thickness wounds were made on the back of nude
Foxn1 mice, splinted with silicone rings, treated with
PBS or tGFP+ DPPSC (n = 5 per group) and covered
with a bandage to prevent the wounds from drying out.
The homogeneous spreading of the cells across the
wound bed was confirmed at day 5 using live fluores-
cence microscopy (Fig. 3a, b). Digital pictures of the
wounds revealed no differences in wound contraction
between treatment regimens (data not shown). At day
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inhibitor of metalloproteinases 2
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11 after wounding, mice were sacrificed and persistent
tGFP+ DPPSC were detected on wound cross-sections
(Fig. 3c, d). Immunofluorescence analyses for tGFP and
αSMA (Fig. 3e-g) revealed that DPPSC were distributed
across the regenerating area and that some DPPSC were
integrated in the αSMA layer of red blood cell (RBC)-
filled blood vessels, consistent with their robust in vitro
SMC differentiation potential. Subsequently, immuno-
fluorescence analysis for CD31 and αSMA (Fig. 3 h, i)
revealed that, while no significant differences were found
between the two groups regarding number and area of
CD31+ vessels (Table 1), the area and percentage of
αSMA-coated blood vessels were statistically signifi-
cantly higher in DPPSC-treated compared to PBS-
treated wounds (Fig. 3j, k and Table 1). In addition, in
agreement with this improved SMC-coverage of the
newly formed vessels, we observed that DPPSC-treated
wounds presented less RBC leakage compared to con-
trols (Fig. 4a, b and Additional file 6: Figure S4a-d).
Laminin immunofluorescence staining for the analysis of
the basement membrane of the endothelium was com-
parable in PBS-treated and DPPSC-treated wounds
(Table 1 and Additional file S6: Figure S4e-f ).
Next, we evaluated the benefit of DPPSC transplantation
on epidermal healing by analysing re-epithelialisation.
While only 40% of the PBS-treated mice showed complete
epithelial coverage of the wound, all DPPSC-treated mice
had complete re-epithelialisation (Table 1). In those PBS-
treated mice that were incompletely re-epithelialised, the
average coverage was 70% ± 10% (Fig. 4a, b). In addition,
the thickness of the epithelium in DPPSC-treated wounds
compared to that of PBS-treated wounds was significantly
lower, resembling that of normal skin outside the wound
(Fig. 4c-e and Table 1). To evaluate dermal healing we
analysed the deposition and organisation of collagen in
the wound borders and centre. The collagen content was
statistically significantly higher in the centre of the
DPPSC-treated wounds compared to the PBS-treated
wounds as indicated by Sirius Red staining under bright
light (Fig. 4f-h and Table 1). The wound margins adjacent
to the normal skin showed no significant difference be-
tween the two groups (Fig. 4 h and Table 1). Furthermore,
the amount of organised (red birefringent) collagen, re-
vealed with polarised light microscopy on the same cross-
sections, was also significantly higher in the centre of the
DPPSC-treated compared to the PBS-treated wounds
(Fig. 4i-k and Table 1) and no statistically significant dif-
ferences were observed in the wound margins (Fig. 4k and
Table 1). Interestingly, unlike in PBS-treated animals, the
values of total and organised collagen in the centre of the
DPPSC-treated wounds were similar to the ones in the
wound margins and normal skin tissue (Fig. 4h, k). These
differences in collagen organisation in the centre of the
wounds were confirmed by immunofluorescence analyses
for collagen type III (COL3), representing firstly formed
more disorganised fibres, and collagen type I (COL1),
representing later formed more organised fibres (Fig. 4l-q
and Table 1). Finally, DPPSC-derived myofibroblasts
(αSMA+tGFP+ cells not associated to vessel structures)
were barely detected in the wound area (Table 1 and
Additional file 6: Figure S4g, h).
The healing potential of DPPSC in dystrophic muscles
DPPSC were injected in the tibialis anterior of Sgcb-null
Rag2-null γc-null and Scid/mdx mice. In Sgcb-null
Rag2-null γc-null mice, DPPSC engraftment in muscle
tissue 20 days after the injection was confirmed by im-
munofluorescence analysis for human lamin A/C
(hLMNA) and laminin (Fig. 5a). The majority of DPPSC
were detected in the interstitial space among fibres,
although human nuclei were occasionally present in
regenerating fibres (Fig. 5a, b). In addition, DPPSC were
integrated in SMC-coated blood vessels and were ex-
pressing αSMA (Fig. 5c). SGCB+ fibres were detected in
DPPSC-injected muscles in Sgcb-null Rag2-null γc-null
mice, while no SGCB+ fibres were detected in control
muscles (Fig. 5d, e). Quantification of the area of vessels
(See figure on previous page.)
Fig. 2 In vitro mesodermal differentiation of DPPSC. a-c Immunofluorescence analysis for VE-cadherin (green; a, b), CD31 (red; a) and vWF (red; b) in
DPPSC differentiated for 28 days to the endothelial lineage (a, b); undifferentiated DPPSC were used as negative control (c). d-f Immunofluorescence
analysis for the smooth muscle markers calponin (green) and αSMA (red) in differentiated DPPSC from passage (P) 5 (d) and P10 (e) cultured in smooth
muscle differentiation medium for 10 days; undifferentiated DPPSC were used as negative control (f). g Immunofluorescence analysis of DPPSC co-
cultured with C2C12 cells at day 5 of myogenic induction. Arrows indicate the presence of human nuclei (stained for hLMNA in green), inside the
formed myotubes expressing MyHC (red). h Immunofluorescence analysis of tGFP+ DPPSC (green) co-cultured with C2C12 cells. Arrows indicate MyHC+
chimeric myotubes. i Immunofluorescence analysis for hLMNA (green) and MyHC (red) in undifferentiated DPPSC was used as a negative control. For
a-i, nuclei are counterstained with DAPI (blue). Scale bars: 100 μm. j Quantitative analysis of DPPSC differentiated towards the endothelial lineage
expressing VE-cadherin (green), vWF or CD31 alone (red), double positive for VE-cadherin and CD31 (left graph in orange) or for VE-cadherin and vWF
(right graph in orange), or none of these markers (blue; n = 3 independent experiments). k Quantitative analysis of DPPSC differentiated towards the
smooth muscle lineage expressing calponin (green), αSMA (red), both smooth muscle markers (orange) or none of these markers (blue) at P5 (left graph)
and P10 (right graph). No statistically significant difference was found (n = 3 independent experiments). l Fusion index analysis in DPPSC-C2C12 co-
cultures (***p < 0.001, n = 6 independent experiments). m Quantitative analysis of the number of MyHC+ myotubes in DPPSC-C2C12 co-cultures
(*p < 0.05, n = 6 independent experiments). For k-m, two-tailed Student’s t test was used and results are displayed as mean ± s.e.m
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positive for vWF and αSMA revealed that DPPSC-
injected muscles had a higher area of vWF+ or αSMA+
vessels compared to control muscles in Sgcb-null Rag2-
null γc-null mice (Fig. 5f-h).
In Scid/mdx, DPPSC engraftment was also con-
firmed (Additional file 7: Figure S5a) and human nu-
clei were mainly localised in the interstitial space and
occasionally in regenerating fibres (Additional file 7:
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Figure S5a-c). Moreover, vWF+ DPPSC were detected
in the EC layer and αSMA+ DPPSC in the SMC layer
of blood vessels (Additional file 7: Figure S7d, e). In
DPPSC-injected muscles, more dystrophin+ fibres
were observed compared to control muscles (Additional
file 7: Figure S5f, g). We could also detect, in serial
sections, dystrophin expression in the same zones where
hLMNA+ DPPSC were present (Additional file 7:
Figure S5h, i), suggesting their direct myogenic con-
tribution. The area of vWF+ or αSMA+ vessels in
DPPSC-injected muscles in Scid/mdx was also higher com-
pared to control muscles (Additional file 7: Figure S5j-l).
Morphometric analysis of muscle tissue revealed that
DPPSC-injected muscles featured a higher frequency of
fibres with larger cross-sectional area when compared to
control muscles in both mouse models (Fig. 6a-c and
Additional file 8: Figure S6a-c). Moreover, Masson’s tri-
chrome staining showed a significant reduction in fibro-
sis in DPPSC-injected dystrophic muscles compared to
controls (Fig. 6d-f and Additional file 8: Figure S6d-f).
This was confirmed by Sirius Red staining (Fig. 6 g-i and
Additional file 8: Figure S6g-i), that revealed significantly
lower collagen content in DPPSC-injected muscles com-
pared to controls.
Interestingly, NADH staining showed that in Sgcb-null
Rag2-null γc-null muscles larger type II fast-glycolytic
fibres were observed in DPPSC-injected muscles com-
pared to control muscles (Fig. 6j-l). Type I slow-
oxidative fibres were comparable in Sgcb-null Rag2-null
γc-null muscles injected with DPPSC and in control
muscles (Fig. 6j, k, m). In Scid/mdx mice, however,
DPPSC-injected muscles featured larger type I and type
II fibres compared to control muscles (Additional file 8:
Figure S6j-m).
In order to analyse the effect of DPPSC on macro-
phage polarisation, we performed immunofluorescence
analyses for the general and proangiogenic M2 macro-
phage markers F4/80 and CD206, respectively. In both
mouse models DPPSC treatment did not alter the total
amount of F4/80+ macrophages (Fig. 7a, c, e and
Additional file 9: Figure S7 a, c, e). However, the amount
of CD206+ cells was significantly higher in DPPSC-
injected compared to control muscles in both mouse
models (Fig. 7b, d, e and Additional file 9: Figure S7b, d, e).
To verify whether the change of macrophage-specific
markers was associated with cytokine profile modifica-
tions, we analysed the presence of cytokines in DPPSC-
injected and control muscles. Our data showed that
several factors involved in M2 transition, including
interleukin (IL)-4, IL-5, IL-6 and GCSF were not influ-
enced by DPPSC treatment. However, the increased
amount of IL-9 and IL-10 in DPPSC-injected muscles
compared to control muscles (Fig. 7f-h and Additional
file 9: Figure S7f ) suggested that these cytokines could
be implicated in M2 transition.
Discussion
In this study, we isolated several DPPSC populations as
previously reported [1, 2, 31]. DPPSC maintained their
typical morphology for 15 passages, i.e., small cells with
Table 1 Effects of DPPSC treatment in the wound healing assay
Wound revascularisation, epidermal and dermal healing at day 11 PBS DPPSC
Revascularisation Number of CD31+ vessels/mm2 tissue 461 ± 49 409 ± 42
mm2 CD31+ vessels/mm2 tissue 0.07 ± 0.01 0.08 ± 0.02
αSMA-coated vessels vs CD31+ vessels (%) 51 ± 5 66 ± 4*
mm2 αSMA-coated vessels/mm2 tissue 0.04 ± 0.01 0.06 ± 0.01*
RBC leakage High Low
Laminin (%) 4.1 ± 1.0 4.8 ± 1.0
Epidermal healing Mice with complete epithelial coverage (%) 40 100
Epithelial coverage (%) 82 ± 10 100 ± 0
Epithelial thickness (μm) 56 ± 4 33 ± 3**
Dermal healing Total collagen (%) wound centre 47 ± 4 61 ± 1**
wound margin 60 ± 4 61 ± 2
Organised collagen (%) wound centre 23 ± 3 38 ± 3**
wound margin 35 ± 1 37 ± 2
Collagen type III (%) wound centre 27 ± 5 12 ± 3*
Collagen type I (%) wound centre 20 ± 5 39 ± 6*
tGFP+ αSMA+ cells not associated to vessels (%) 0 ± 0 1.3 ± 0.7
DPPSC dental pulp pluripotent-like stem cells, αSMA α-smooth muscle actin, RBC red blood cell, tGFP turbo green fluorescent protein
*p < 0.05, **p < 0.01 vs PBS treatment, n = 5 animals/group. Results are displayed as mean ± s.e.m.
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large nuclei relative to the volume of the cytoplasm, a
characteristic shared with other hPSCs [32]. In addition,
DPPSC expressed pluripotency markers, including
OCT4. The detection of OCT4 expression by PCR has
been controversial, due to the presence of transcrip-
tional variants of the OCT4 gene and pseudogenes that
encode proteins that do not participate in pluripotency
maintenance [33, 34]. Therefore, for our analyses, we
used the primers from Xu et al. [33] that specifically
amplify the mRNA variant 1 or OCT4A, which synthe-
sises the key transcription factor for maintaining self-
renewal and pluripotency. The presence of NANOG
and SOX2 proteins was also confirmed by immuno-
fluorescence analysis. DPPSC were also characterised
by the presence of ALP activity, which is known to be
present in adult and pluripotent stem cells [35, 36]. A
main concern for potential clinical application based on
stem cell therapy is the genetic stability [37, 38]. In this
(See figure on previous page.)
Fig. 4 Effect of DPPSC on epidermal and dermal healing at day 11. a, b Haematoxylin and eosin staining showing the increased epithelial coverage in
DPPSC-treated wounds (b) compared to PBS-treated ones (a). Wound boundaries and the length covered by the epidermis are indicated by white
arrowheads and black lines, respectively. Presence of red blood cell (RBC) leakage (indicated by asterisk in a, enlarged in inset) can be observed in the
PBS-treated condition, while RBCs are contained in blood vessels in DPPSC-treated wounds (b, insets). Scale bars: 200 μm. c, d Haematoxylin and eosin
staining showing the increased epithelial thickness in the wound area (wound boundaries are indicated by white arrowheads) in PBS-treated mice
(c) compared to DPPSC-treated mice (d). Scale bars: 200 μm. e Quantification of the epithelial thickness in μm. ** p < 0.01, n = 5 mice/group. f, g Sirius
Red staining visualised by bright field microscopy of the central part of wounds treated with PBS (f) or DPPSC (g) for the analysis of total
collagen in the wound matrix. Scale bars: 100 μm. h Quantification of the total collagen present in the wound centre and margins of mice treated with
PBS or DPPSC. **p < 0.01, n = 5 mice/group. i, j Sirius Red staining of the same sections of wounds treated with PBS (i) or DPPSC (j) as in f, g visualised
by polarised light microscopy for the analysis of organised (red birefringent) collagen in the wound matrix. Scale bars: 100 μm. k Quantification of the
organised collagen present in the wound centre and margins of mice treated with PBS or DPPSC. **p< 0.01, n= 5 mice/group. l,m Immunofluorescence
analysis for collagen type III (COL3; in green) in wounds treated with PBS (l) or DPPSC (m). n Quantification of the percentage of wound area positive for
COL3 I in the wound centre of mice treated with PBS or DPPSC. *p< 0.05, n= 5 mice/group. o, p Immunofluorescence analysis for collagen type I (COL1;
in red) in wounds treated with PBS (o) or DPPSC (p). q Quantification of the percentage of wound area positive for COL1 in the wound centre of mice
treated with PBS or DPPSC. *p< 0.05, n= 5 mice/group. For l, m, o, p, nuclei are counterstained with DAPI (blue); scale bars: 100 μm. Two-tailed Student’s t
test was used for e, n, q; one-way ANOVA test was used for h, k; results are displayed as mean ± s.e.m
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study, by using the sCGH technique [30], we confirmed
that DPPSC from ten different donors showed no
chromosomal abnormalities for at least 15 passages.
Functional blood vessels consist of mainly two distinct
cell types, i.e., ECs (lining the inside) and vascular SMCs
(surrounding the ECs) [3]. We provided evidence that
DPPSC differentiate into functional ECs expressing typical
endothelial markers (VEGFR2, CD31, VE-cadherin and
vWF) at mRNA and protein levels. The addition of BMP4,
an inducer of mesoderm, in the first days of the differenti-
ation [39, 40] could be further explored to optimise the
endothelial potential of DPPSC. The percentages of
differentiated cells that expressed typical SMC markers
were higher as compared to EC differentiation. In
addition, undifferentiated DPPSC maintained the SMC
differentiation capacity up to passage 10. During embry-
onic development, ectomesenchymal cells in the cranial
neural folds have the competence to form SMCs [41, 42].
Thus, the capacity of DPPSC to undergo SMC differenti-
ation could be related to their neuroectodermal differenti-
ation potential and is extremely important for in vivo
applications where new functional blood vessels are
needed.
a b c
d e f
g h i
j
k
l m
Fig. 6 Histological, morphometric and fibre type analyses after DPPSC injection in dystrophic Sgcb-null Rag2-null γc-null mice. a, b Haematoxylin
and eosin staining in control (a) or DPPSC-injected (b) Sgcb-null Rag2-null γc-null muscles. Scale bars: 100 μm. c Quantitative frequency distribution
analysis of the cross-sectional area of the fibres in Sgcb-null Rag2-null γc-null muscles. *p < 0.05, n = 3 for each group. d, e Masson’s trichrome staining
in control (d) or DPPSC-injected (e) Sgcb-null Rag2-null γc-null muscles revealing areas of fibrosis (blue). Scale bars: 100 μm. f Quantitative analysis of the
percentage of fibrosis per field in Sgcb-null Rag2-null γc-null muscles. *p < 0.05, n = 4 for each group. g, h Sirius Red staining visualised by bright field
microscopy in control (g) or DPPSC-injected (h) Sgcb-null Rag2-null γc-null muscles for the analysis of total collagen. Scale bars: 100 μm. i Quantification
of the total collagen present in Sgcb-null Rag2-null γc-null muscles. *p < 0.05, n = 4 for each group. j, k NADH staining of control (j) and DPPSC-injected
(k) Sgcb-null Rag2-null γc-null muscles, showing oxidative fibres in blue and glycolytic fibres in white. Scale bars: 100 μm. l, m Quantitative frequency
distribution analysis of the cross-sectional area of type II fast-glycolytic (l) or type I slow-oxidative (m) fibres in the NADH staining in Sgcb-null Rag2-null
γc-null muscles injected with DPPSC compared to control muscles. *p < 0.05, n = 3 for each group. For c, f, i, l, m, two-tailed Student’s t test was used
and results are displayed as mean ± s.e.m
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To analyse the revascularisation potential of DPPSC in
vivo, we first used a full thickness wound healing assay
described by Hendrickx et al. [18] and in addition stud-
ied the effect on wound closure and (epi)dermal healing
after 11 days. DPPSC were shown for the first time to
differentiate into perivascular SMCs, demonstrating a
direct contribution to vascular SMC coating of blood
vessels. In addition, a significant increase in the percent-
age and area of mature αSMA+-coated vessels was found
in the healing wound bed of DPPSC-treated mice com-
pared to controls. This could be likely due to a paracrine
effect of DPPSC, able to secrete growth factors such as
ANG, VEGF, PDGF-BB, HGF, PlGF and osteopontin
(OPN). Indeed, PDGF-BB, PlGF and OPN are known to
attract SMCs and stabilise vessels [43–46]. In agreement
with a more stable wound vasculature, granulation tissue
in DPPSC-treated wounds featured less RBC leakage.
Other studies reported that intramyocardial injection of
human dental pulp stem cells (DPSCs) in a rat model of
myocardial infarction, resulted in a better neovasculari-
sation in cell-treated animals compared to controls and
an improvement in cardiac function [47]. Along with an
increased maturation of the wound vasculature, we here
demonstrated that all DPPSC-treated wounds showed
complete epithelial coverage in contrast to only 40% of
PBS-treated wounds and that the average epithelial
thickness was significantly lower in DPPSC-treated
wounds, suggesting that both the epithelial coverage and
the subsequent involution of the hyperplastic neoepider-
mis were accelerated in DPPSC-treated mice. Our novel
Control
Sgcb/Rag2/ c-null
DPPSC-injected 
Sgcb/Rag2/ c-null
Ctrl
Sgcb/Rag2/ c-null
F4/80 DAPI CD206  DAPIa
c
e
DPPSC-inj. 
Sgcb/Rag2/ c-null
F4/80 DAPI CD206  DAPI
b
d
Ctrl 
Sgcb/Rag2/ c-null
DPPSC-inj. 
Sgcb/Rag2/ c-null
F 4 /8 0
+
c e lls C D 2 0 6
+
c e lls
0
1 0 0
2 0 0
3 0 0
4 0 0
5 0 0
N
u
m
b
e
r
o
f
c
e
ll
s
p
e
r
m
m
2
ti
s
s
u
e
C tr l S g c b /R a g 2 / c -n u l l
D P P S C -in j. S g c b /R a g 2 / c -n u l l
*
f g
IL-10IL-9
IL
-9
s
p
o
t
in
te
n
s
i t
y
(a
rb
it
r a
ry
u
n
it
s
)
C t rl
S g c b /R a g 2 /
c -n u ll
D P P S C -in j.
S g c b /R a g 2 /
c -n u ll
0
1 0 0
2 0 0
3 0 0
4 0 0
5 0 0
*
h
I L
- 1
0
s
p
o
t
in
t e
n
s
i t
y
(a
rb
it
r a
ry
u
n
it
s
)
C t rl
S g c b /R a g 2 /
c -n u ll
D P P S C -in j.
S g c b /R a g 2 /
c -n u ll
0
1 0 0
2 0 0
3 0 0
4 0 0
5 0 0 *
Positive controls
Fig. 7 Macrophage and cytokine analyses after DPPSC injection in dystrophic Sgcb-null Rag2-null γc-null mice. a-d Immunofluorescence analysis
for macrophage-specific F4/80 (red; a, c) and proangiogenic M2 macrophage-specific CD206 (green; b, d) in control (a, b) or DPPSC-injected
(c, d) Sgcb-null Rag2-null γc-null muscles. Scale bars: 50 μm. e Quantitative analysis of the number of cells expressing F4/80 and CD206
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data regarding DPPSC secretion support an indirect
mechanism for the accelerated epithelial coverage medi-
ated by the angiogenic factors VEGF, ANG and PDGF-
BB that improved oxygen delivery to migrating keratino-
cytes. In addition, DPPSC secreted a huge amount of
HGF and TIMP-2 (and a tiny amount of IL-6), which
have been shown to promote keratinocyte migration [48–
50]. In further support of a more mature and advanced
status of the wound healing process in DPPSC-treated
mice, dermal wound collagen deposition was significantly
higher in the centre of DPPSC-treated wounds, better re-
sembling the characteristics of normal skin. It is likely that
the growth factors secreted by DPPSC could be respon-
sible at least in part for the beneficial effect of DPPSC
treatment in the collagen deposition. Indeed, DPPSC pro-
duction of TGF-β could promote fibroblast proliferation
and collagen synthesis [17].
DPPSC injected in dystrophic muscles differentiated
into both ECs and SMCs. Indeed, DPPSC were detected
in the inner and outer part of vessels in dystrophic Scid/
mdx mice. In dystrophic Sgcb-null Rag2-null γc-null
mice, cells were often detected in the outer part of ves-
sels, also suggesting a significant involvement in revas-
cularisation. In a recent study [28], it was observed that
human DPSCs, even though they were pre-differentiated
towards the skeletal muscle lineage, were localised in the
endothelium of newly generated vessels after their trans-
plantation in Scid/mdx mice. We quantified the area of
vessels present in the muscles and found that DPPSC-
injected muscles had a significantly higher area of vWF+
and of αSMA+ vessels compared to control muscles, fur-
ther supporting the revascularisation potential of
DPPSC. Intriguingly, while DPPSC increased the SMC
coverage rate but not the total number of blood vessels
in healing wounds, they increased the total number of
vessels in both dystrophic models. We speculate this dif-
ferential revascularisation response may be in part re-
lated to a different time range of both healing processes,
the duration being twice as long in the dystrophic
models. The longer duration of the latter would be per-
missive for the longer term required for DPPSC to dif-
ferentiate in vitro into mature ECs as compared to
SMCs. In addition, the fact that the efficiency of DPPSC
in vitro EC differentiation was not as high as SMC dif-
ferentiation could also partially explain their differential
revascularisation response.
In this study, we also provided evidence that DPPSC
from different donors are capable of fusing with mouse
C2C12 cells after 5 days of myogenic induction, thereby
generating hybrid myotubes. The capacity to fuse was
maintained for at least ten passages. We also observed
that the presence of DPPSC enhanced the differentiation
potential of C2C12 cells, increasing the fusion index and
the number of MyHC+ myotubes. Consistent with our
results, a recent study using DPSCs demonstrated that
DPSCs are able to fuse with C2C12 cells forming hybrid
myotubes, although myogenic induction was prolonged
to 14 days [28]. Similarly to DPSCs, DPPSC contributed
to myogenic regeneration when transplanted in Scid/
mdx mice. Moreover, the results presented here demon-
strated for the first time that DPPSC can also contribute
to regeneration of muscle fibres in vivo when injected
intramuscularly in Sgcb-null dystrophic mice. This is of
clinical relevance since in contrast to mdx mice, Sgcb-
null mice do not feature revertant fibres and thus exhibit
severe muscular dystrophy, better replicating the human
disease [23, 25, 51]. We also detected the presence of
beta-sarcoglycan+ fibres in DPPSC-injected Sgcb-null
Rag2-null γc-null mice. In addition, dystrophic muscles
from both murine models injected with DPPSC featured
a higher frequency of fibres with larger cross-sectional
area and reduced fibrosis and collagen content, expand-
ing the previous report in Scid/mdx mice using DPSCs
[28] also for the limb-girdle muscular dystrophy mouse
model Sgcb-null Rag2-null γc-null. Moreover, DPPSC-
injected dystrophic muscles showed a higher frequency
of type II fast-glycolytic fibres with higher cross-
sectional area compared to controls in both dystrophic
mouse models. This is particularly relevant since it has
been proven that fast glycolytic muscle fibres are prefer-
entially affected in DMD [52] and that at least in mdx
mice they are highly susceptible to degeneration-
regeneration cycles [53, 54]. Therefore, we hypothesise
that DPPSC play a role in reducing the degeneration of
glycolytic fibres in these mice. Mechanistic insights to
explain these beneficial effects are still unknown and fur-
ther experiments are needed to address this issue.
Nevertheless, we hypothesise that the detected growth
factors secreted by DPPSC could play a synergistic role
in the positive impact of DPPSC on dystrophic muscle.
For instance, HGF is considered the only growth factor
able to activate satellite cells, the muscle-resident myo-
genic stem cells [55]. In addition, DPPSC injection in
dystrophic skeletal muscles also resulted in an increase
of CD206+ cells compared to control muscles, while the
total number of F4/80+ cells was maintained. F4/80 is a
well-known macrophage-specific marker [56] and
CD206 (mannose receptor) has been used to distinguish
M2 macrophages with proangiogenic [57] and anti-
inflammatory properties [58] from pro-inflammatory M1
macrophages. Thus, the higher presence of CD206+ cells
in DPPSC-injected muscles further explained the benefi-
cial effect of DPPSC treatment on blood vessel growth
and prevention of muscle degeneration. Unfortunately,
xenograft models imply the use of immunodeficient ani-
mals that are a clear limitation to investigate cellular and
molecular mechanisms connected to the immune system
and likely in part responsible for the beneficial effect of
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DPPSC. In previous studies, other adult stem cells have
shown the capacity to activate M2 macrophages [59].
Similarly to those studies, it is likely that in DPPSC-
treated muscles M2 macrophages were engaged through
paracrine signalling. Interestingly, DPPSC-injected mus-
cles presented significantly higher levels of IL-9 and IL-
10 compared to controls. Indeed, several reports have
shown that IL-10 is primarily involved in the M2 transi-
tion and promotes muscle regeneration after acute and
chronic injury [60, 61]. However, in our experiments, IL-
13, also implicated in M2 transition, was only slightly
affected. Finally, IL-9 still remains an understudied cyto-
kine [62]. Nevertheless, it is known to be mainly pro-
duced in response to the M2-related cytokines IL-4 and
TGF-β [63] and to promote progenitor cell proliferation
and reduce apoptosis [64], thus probably contributing to
a better regeneration in DPPSC-injected muscles.
Conclusions
Taken together, our results showed that DPPSC positively
impact on dystrophic skeletal muscles and wound healing
assays. Although our findings are not conclusive to deter-
mine the modus operandi of transplanted DPPSC, it is
clear that they act mainly through their revascularisation
potential, paracrine signalling effects and limited smooth
and skeletal muscle direct contribution. Further studies
are necessary to test whether these actions could function-
ally improve muscle histopathologies.
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Additional file 8: Figure S6. Histological, morphometric and fibre type
analyses after DPPSC injection in dystrophic Scid/mdx mice. a, b Haematoxylin
and eosin staining in control (a) or DPPSC-injected (b) Scid/mdx
muscles. Scale bars: 100 μm. c Quantitative frequency distribution analysis
of the cross-sectional area of the fibres in Scid/mdx muscles. *p < 0.05, n = 3
for each group. d, e Masson’s trichrome staining in control (d) or DPPSC-
injected (e) Scid/mdx muscles revealing areas of fibrosis (blue). Scale bars:
100 μm. f Quantitative analysis of the percentage of fibrosis per field in Scid/
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visualised by bright field microscopy in control (g) or DPPSC-injected (h)
Scid/mdx muscles for the analysis of total collagen. Scale bars: 100 μm. i
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0.001, n = 8 for each group. j, k NADH staining of control (j) and DPPSC-
injected (k) Scid/mdx muscles, showing oxidative fibres in blue and glycolytic
fibres in white. Scale bars: 100 μm. l, m Quantitative frequency distribution
analysis of the cross-sectional area of type II fast-glycolytic (l) or type I slow-
oxidative (m) fibres in the NADH staining in Scid/mdx muscles injected with
DPPSC compared to control muscles. *p < 0.05, n = 3 for each group. For c,
f, i, l, m, two-tailed Student’s t test was used and results are displayed as
mean ± s.e.m.. (PDF 310 kb)
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analysis of macrophage-specific F4/80 (red; a, c) and proangiogenic M2
macrophage-specific CD206 (green; b, d) in control (a, b) or DPPSC-
injected (c, d) Scid/mdx muscles. Scale bars: 50 μm. e Quantitative analysis
of the number of cells expressing F4/80 and CD206 macrophage markers
per mm2 of tissue in Scid/mdx muscles. *p < 0.05, n = 9 for each group;
two-tailed Student’s t test was used and results are displayed as mean ±
s.e.m.. f Cytokine antibody arrays showing the apparent increment in spot
intensity in IL-9, IL-10 and IL-13 in DPPSC-injected (right panel) compared
to control (left panel) Scid/mdx muscles. (PDF 51 kb)
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